The Leukaemia Foundation provided consumer comments to the Pharmaceutical Benefits Advisory Committee (PBAC) in relation to Otsuka Australia Pharmaceutical’s resubmission for decitabine and cedazuridine (Inqovi®) for high-risk MDS and CMML.
A lot of ‘world firsts’ are involved in an Australian clinical trial that is taking a precision medicine approach to treating CMML, a neglected and serious rare blood cancer that is poorly understood.
Dr Devendra Hiwase thinks every patient with this rare form of blood cancer should have molecular profiling.
Tony Wakely shares his personal journal, where he documents his experiences with MDS and AML.
After a misdiagnosis and delayed biopsy, Steph Eliot was finally diagnosed with Stage 2 Hodgkin lymphoma (HL).
Julian Lindsay’s goal is to set up an international study aimed at improving survival and quality of life through drug optimisation.
An Australian study will examine the immune response to the COVID-19 vaccine in patients with the low-grade non-Hodgkin lymphomas.
Associate Professor Michael Dickinson says CAR T-cell therapy is a 'revolutionary step forward'.
In her own words, Rowena McLean shares her harrowing four-and-a-half-year blood cancer journey in the lead up to World Blood Cancer Day, 28 May 2021.
